Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan

BACKGROUND AND OBJECTIVES: Nephrolithiasis is a common health problem in autosomal dominant polycystic kidney disease (ADPKD) and significantly contributes to patient morbidity. Recently, Tolvaptan has been introduced for the treatment of ADPKD, but whether it is associated with alterations of the u...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin J Am Soc Nephrol
Hlavní autoři: Bargagli, Matteo, Dhayat, Nasser A., Anderegg, Manuel, Semmo, Mariam, Huynh-Do, Uyen, Vogt, Bruno, Ferraro, Pietro Manuel, Fuster, Daniel G.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Nephrology 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7341771/
https://ncbi.nlm.nih.gov/pubmed/32527945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.13861119
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky